Endogenous ouabain is not ouabain

Hypertension

Volumn 64, Issue 4, 2014, Pages 680-683

  Lewis, Lynley K ^a   Yandle, Timothy G ^a   Hilton, Philip J ^b   Jensen, Berit P ^c   Begg, Evan J ^a   Nicholls, M Gary ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); OUABAIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; HUMAN; IMMUNOASSAY;

ANIMALS; BLOOD PRESSURE; HUMANS; IMMUNOASSAY; OUABAIN; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84914669732     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03919     Document Type: Review

References (43)

1. De Wardener HE, Mills IH, Clapham WF, Hayter CJ. Studies on the efferent mechanism of the sodium diuresis which follows the administration of intravenous saline in the dog. Clin Sci. 1961;21: 249-258.
2. Nutbourne DM, Howse JD, Schrier RW, Talner LB, Ventom MG, Verroust PJ, De Wardener HE. The effect of expanding the blood volume of a dog on the short-circuit current across an isolated frog skin incorporated in the dog's circulation. Clin Sci. 1970;38: 629-648.
3. Clarkson EM, Talner LB, De Wardener HE. The effect of plasma from blood volume expanded dogs on sodium, potassium and PAH transport of renal tubule fragments. Clin Sci. 1970;38: 617-627.
4. Cole CH, Balfe JW, Welt LG. Induction of a ouabain-sensitive ATPase defect by uremic plasma. Trans Assoc Am Physicians. 1968;81: 213-220.
5. Edmondson RP, Thomas RD, Hilton PJ, Patrick J, Jones NF. Abnormal leucocyte composition and sodium transport in essential hypertension. Lancet. 1975;1: 1003-1005.
6. Hilton PJ. Factors influencing leucocyte sodium transport in hypertension. Klin Wochenschr. 1985;63(suppl 3): 49-51.
7. Ludens JH, Clark MA, DuCharme DW, Harris DW, Lutzke BS, Mandel F, Mathews WR, Sutter DM, Hamlyn JM. Purification of an endogenous digitalislike factor from human plasma for structural analysis. Hypertension. 1991;17(6 Pt 2): 923-929.
8. Mathews WR, DuCharme DW, Hamlyn JM, Harris DW, Mandel F, Clark MA, Ludens JH. Mass spectral characterization of an endogenous digitalislike factor from human plasma. Hypertension. 1991;17(6 Pt 2): 930-935.
9. Harris DW, Clark MA, Fisher JF, Hamlyn JM, Kolbasa KP, Ludens JH, DuCharme DW. Development of an immunoassay for endogenous digitalislike factor. Hypertension. 1991;17(6 Pt 2): 936-943.
10. Hamlyn JM, Blaustein MP, Bova S, DuCharme DW, Harris DW, Mandel F, Mathews WR, Ludens JH. Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci U S A. 1991;88: 6259-6263.
11. Bova S, Blaustein MP, Ludens JH, Harris DW, DuCharme DW, Hamlyn JM. Effects of an endogenous ouabainlike compound on heart and aorta. Hypertension. 1991;17(6 Pt 2): 944-950.
12. Editorial. Welcome to ouabain - A new steroid hormone. Lancet. 1991;338: 543-544.
13. Laredo J, Hamilton BP, Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocrinology. 1994;135: 794-797.
14. Laredo J, Hamilton BP, Hamlyn JM. Secretion of endogenous ouabain from bovine adrenocortical cells: Role of the zona glomerulosa and zona fasciculata. Biochem Biophys Res Commun. 1995;212: 487-493.
15. Laredo J, Shah JR, Lu ZR, Hamilton BP, Hamlyn JM. Angiotensin II stimulates secretion of endogenous ouabain from bovine adrenocortical cells via angiotensin type 2 receptors. Hypertension. 1997;29(1 Pt 2): 401-407.
16. Valdes R Jr, Graves SW, Brown BA, Landt M. Endogenous substance in newborn infants causing false positive digoxin measurements. J Pediatr. 1983;102: 947-950.
17. Morris JF, McEachern MD, Poston L, Smith SE, Mulvany MJ, Hilton PJ. Evidence for an inhibitor of leucocyte sodium transport in the serum of neonates. Clin Sci (Lond). 1987;73: 291-297.
18. Hilton PJ, White RW, Lord GA, Garner GV, Gordon DB, Hilton MJ, Forni LG, McKinnon W, Ismail FM, Keenan M, Jones K, Morden WE. An inhibitor of the sodium pump obtained from human placenta. Lancet. 1996;348: 303-305.
19. Wright DA, Lord GA, White RW, Hilton MJ, Gordon DB, Hilton PJ. Evidence for circulating bufenolide in a volume-expanded patient. Lancet. 1997;350: 409.
20. Nicholls MG, Lewis LK, Yandle TG, Lord G, McKinnon W, Hilton PJ. Ouabain, a circulating hormone secreted by the adrenals, is pivotal in cardiovascular disease. Fact or fantasy? J Hypertens. 2009;27: 3-8.
21. Doris PA, Jenkins LA, Stocco DM. Is ouabain an authentic endogenous mammalian substance derived from the adrenal? Hypertension. 1994;23: 632-638.
22. Gomez-Sanchez EP, Foecking MF, Sellers D, Blankenship MS, Gomez- Sanchez CE. Is the circulating ouabain-like compound ouabain? Am J Hypertens. 1994;7(7 Pt 1): 647-650.
23. Lewis LK, Yandle TG, Lewis JG, Richards AM, Pidgeon GB, Kaaja RJ, Nicholls MG. Ouabain is not detectable in human plasma. Hypertension. 1994;24: 549-555.
24. Manunta P, Ferrandi M, Bianchi G, Hamlyn JM. Endogenous ouabain in cardiovascular function and disease. J Hypertens. 2009;27: 9-18.
25. Jacobs BE, Liu Y, Pulina MV, Golovina VA, Hamlyn JM. Normal pregnancy: Mechanisms underlying the paradox of a ouabain-resistant state with elevated endogenous ouabain, suppressed arterial sodium calcium exchange, and low blood pressure. Am J Physiol Heart Circ Physiol. 2012;302: H1317-H1329.
26. Bignami E, Casamassima N, Frati E, et al. Preoperative endogenous ouabain predicts acute kidney injury in cardiac surgery patients. Crit Care Med. 2013;41: 744-755.
27. Manunta P, Messaggio E, Casamassima N, Gatti G, Carpini SD, Zagato L, Hamlyn JM. Endogenous ouabain in renal Na(+) handling and related diseases. Biochim Biophys Acta. 2010;1802: 1214-1218.
28. Blanco G, Wallace DP. Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2013;305: F797-F812.
29. Manunta P, Iacoviello M, Forleo C, Messaggio E, Hamlyn JM, Lucarelli K, Guida P, Romito R, De Tommasi E, Bianchi G, Rizzon P, Pitzalis MV. High circulating levels of endogenous ouabain in the offspring of hypertensive and normotensive individuals. J Hypertens. 2005;23: 1677-1681.
30. Adrogué HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. N Engl J Med. 2007;356: 1966-1978.
31. Manunta P, Hamlyn JM, Simonini M, Messaggio E, Lanzani C, Bracale M, Argiolas G, Casamassima N, Brioni E, Glorioso N, Bianchi G. Endogenous ouabain and the renin-angiotensin-aldosterone system: Distinct effects on Na handling and blood pressure in human hypertension. J Hypertens. 2011;29: 349-356.
32. Blaustein MP, Leenen FH, Chen L, Golovina VA, Hamlyn JM, Pallone TL, Van Huysse JW, Zhang J, Wier WG. How NaCl raises blood pressure: A new paradigm for the pathogenesis of salt-dependent hypertension. Am J Physiol Heart Circ Physiol. 2012;302: H1031-H1049.
33. Nicholls MG, Richards AM, Lewis LK, Yandle TG. Ouabain: A new steroid hormone? Lancet. 1995;346: 1381-1382.
34. Hamlyn JM, Hamilton BP, Manunta P. Endogenous ouabain, sodium balance and blood pressure: A review and a hypothesis. J Hypertens. 1996;14: 151-167.
35. Pidgeon GB, Lewis LK, Yandle TG, Richards AM, Nicholls MG. Endogenous ouabain, sodium balance and blood pressure. J Hypertens. 1996;14: 169-171.
36. Naruse K, Naruse M, Tanabe A, Yoshimoto T, Watanabe Y, Kurimoto F, Horiba N, Tamura M, Inagami T, Demura H. Does plasma immunoreactive ouabain originate from the adrenal gland? Hypertension. 1994;23(1 suppl): I102-I105.
37. Dvela M, Rosen H, Ben-Ami HC, Lichtstein D. Endogenous ouabain regulates cell viability. Am J Physiol Cell Physiol. 2012;302: C442-C452.
38. Hamlyn JM, Blaustein MP. Salt sensitivity, endogenous ouabain and hypertension. Curr Opin Nephrol Hypertens. 2013;22: 51-58.
39. Funder JW. Aldosterone, sodium, and hypertension: Lessons from torcetrapib? Hypertension. 2010;55: 221-223.
40. Baecher S, Kroiss M, Fassnacht M, Vogeser M. No endogenous ouabain is detectable in human plasma by ultra-sensitive UPLC-MS/MS. Clin Chim Acta. 2014;431: 87-92.
41. Ferrari P, Ferrandi M, Valentini G, Bianchi G. Rostafuroxin: An ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2006;290: R529-R535.
42. Wenceslau CF, Rossoni LV. Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: The role of Na+K+-ATPase/ cSRC pathway. J Hypertens. 2014;32: 542-554.
43. Staessen JA, Thijs L, Stolarz-Skrzypek K, et al. Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): A randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. Trials. 2011;12: 13.